证券代码：001367 证券简称：海森药业 公告编号：2025-053 浙江海森药业股份有限公司 关于 2024 年限制性股票激励计划预留授予登记完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 限制性股票预留授予日：2025年9月11日 预留授予的限制性股票上市日：2025年10月30日 预留授予的限制性股票登记数量：42.4760万股，占本激励计划预留授予 日公司股本总额的0.2796%。 限制性股票来源：公司向激励对象定向发行的本公司A股普通股股票 根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交 易所、中国证券登记结算有限责任公司深圳分公司的有关规定，浙江海森药业股 份有限公司（以下简称"公司"）完成了2024年限制性股票激励计划（以下简称 "本次激励计划"或"本激励计划"）预留授予登记工作，现将有关事项说明如 下： 一、本次激励计划已履行的相关审批程序 （一）2024年9月12日，公司召开第三届董事会第七次会议，审议通过了《关 于<浙江海森药业股份有限公司2024年限制性股票激励计划（草案）>及其摘要 的议 ...

Core Insights - The company, Haisen Pharmaceutical (001367.SZ), reported a strong performance in its Q3 2025 financial results, achieving a revenue of 117 million yuan, representing a year-on-year growth of 6.74% [1] Group 1: Company Performance - Haisen Pharmaceutical maintains a stable operational performance despite a complex external environment [1] - The company has a diverse product portfolio, including active pharmaceutical ingredients (APIs) and solid formulations, with leading products such as Paroxetine Hydrochloride and Amikacin side-chain PHBA [1] - The market share for Sucralfate is approximately 60%, ranking first internationally, while the domestic market share for Amikacin side-chain PHBA and Methylsulfonylmethane is also over 60% [1] Group 2: Market and Expansion - The company has sufficient market orders for its main products, indicating a robust supply and demand situation [1] - Haisen Pharmaceutical is actively advancing the construction of a new green and intelligent pharmaceutical production base to enhance production capacity [1] - The company is expanding its market presence through a global layout, optimizing its market structure [1] Group 3: Strategic Partnerships - The company has established long-term cooperative relationships with several strategic partners, some lasting over 20 years, which has built a solid foundation for collaboration [2] - Haisen Pharmaceutical has formed stable partnerships with leading global clients, including TEVA, across multiple products [2]

Core Viewpoint - Haosen Pharmaceutical reported a revenue of 359 million yuan for the first three quarters of 2025, marking a year-on-year growth of 12.13%, and a net profit attributable to shareholders of 88 million yuan, with a growth of 1.45% [1] Financial Performance - The total assets of Haosen Pharmaceutical reached 1.569 billion yuan, reflecting a year-on-year increase of 5.55% [1] - Revenue growth of 12.13% and net profit growth of 1.45% indicate stable financial performance despite market challenges [1] Innovation and R&D - The company prioritizes technological innovation and has established a strong mechanism for innovation through collaborations with universities and research institutions [1] - Haosen Pharmaceutical holds 25 authorized patents, with 23 being invention patents, covering key preparation processes and equipment [1] - The collaboration with Hangzhou Haosen Drug Research Institute has enhanced R&D efficiency and market responsiveness [1] Market Expansion - The company is actively expanding into high-end markets in the Americas and Europe, enhancing brand influence through participation in international exhibitions [1] - Establishing long-term partnerships with leading global clients like TEVA has strengthened its position in the global pharmaceutical supply chain [1] Industry Outlook - Haosen Pharmaceutical anticipates continued growth in the emerging pharmaceutical sector, viewing the bulk procurement of chemical drugs as an opportunity for raw material pharmaceutical companies [1]

Core Insights - The company reported a revenue of 116,781,310.01 yuan for the third quarter of 2025, representing a year-on-year increase of 6.74% [2] - The net profit attributable to shareholders of the listed company was 27,415,463.98 yuan, showing a year-on-year decrease of 5.17% [2] Financial Performance - Revenue for Q3 2025: 116.78 million yuan, up 6.74% year-on-year [2] - Net profit for Q3 2025: 27.42 million yuan, down 5.17% year-on-year [2]

Core Insights - The company reported a revenue of 359 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 12.13% [1] - The net profit attributable to shareholders for the same period was approximately 88.21 million yuan, showing a year-on-year increase of 1.45% [1] - In the third quarter, the company achieved a revenue of 117 million yuan, which is a year-on-year increase of 6.74% [1] - The net profit for the third quarter was approximately 27.42 million yuan, indicating a year-on-year decline of 5.17% [1]

Core Viewpoint - Haosen Pharmaceutical (001367.SZ) reported a year-on-year increase in revenue and net profit for the first three quarters of the year, indicating stable growth despite a slight decline in net profit after excluding non-recurring items [1] Financial Performance - The company's operating revenue for the first three quarters reached 359 million yuan, representing a year-on-year growth of 12.13% [1] - The net profit attributable to shareholders of the listed company was approximately 88.21 million yuan, showing a year-on-year increase of 1.45% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was about 84.76 million yuan, reflecting a year-on-year decline of 1.56% [1]

Group 1 - The company, Haishen Pharmaceutical, announced that its 17th board meeting of the third session will be held on October 21, 2025, to review the proposal for the third quarter report of 2025 [1] - The meeting will take place in the company's conference room in a physical format [1] Group 2 - The article highlights the need to shift funding focus from excessive investment in housing and infrastructure to enhancing investments in the livelihood sector [1] - This perspective is part of a broader discussion on the "15th Five-Year Plan" and emphasizes the importance of prioritizing social welfare [1]

Core Viewpoint - Haosen Pharmaceutical (001367.SZ) reported a year-on-year revenue increase of 12.13% for the first three quarters of 2025, reaching 359 million yuan [1] Financial Performance - The company's net profit attributable to shareholders was 88.21 million yuan, reflecting a year-on-year growth of 1.45% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 84.76 million yuan, showing a year-on-year decrease of 1.56% [1] - Basic earnings per share stood at 0.59 yuan [1]

智通财经APP讯，海森药业(001367.SZ)发布2025年三季度报告，该公司前三季度营业收入为3.59亿元， 同比增长12.13%。归属于上市公司股东的净利润为8820.96万元，同比增长1.45%。归属于上市公司股东 的扣除非经常性损益的净利润为8475.8万元，同比减少1.56%。基本每股收益为0.59元。 ...

南财智讯10月21日电，海森药业公告，2025年前三季度公司实现营业收入3.59亿元，同比增长12.13%； 归属于上市公司股东的净利润0.88亿元，同比增长1.45%。基本每股收益0.59元，同比增长1.72%。 ...